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Original Article
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Background: Circulating tumor cells (CTC) in non-small cell lung cancer (NSCLC) patients are 
a prognostic and possible therapeutic marker, but have a low frequency of appearance. Diagnostic 
leukapheresis (DLA) concentrates CTC and mononuclear cells from the blood. We evaluated a protocol 
using two VyCAP microsieves to filter DLA product of NSCLC patients and enumerate CTC, compared 
with CellSearch as a gold standard. 
Methods: DLA was performed in NSCLC patients before starting treatment. DLA product equaling 2×108 
leukocytes was diluted to 9 mL with CellSearch dilution buffer in a Transfix CTC tube. Within 72 hours the 
sample was filtered with a 7 μm pore microsieve and subsequently over a 5μm pore microsieve. CTC were 
defined as nucleated cells which stained for cytokeratin, but lacked CD45 and CD16. CellSearch detected 
CTC in the same volume of DLA. 
Results: Of 29 patients a median of 1.4 mL DLA product (range, 0.5–4.1) was filtered (2% of total 
product) successfully in 93% and 45% of patients using 7 and 5 μm pores, respectively. Two DLA products 
were unevaluable for CTC detection. Clogging of the 5 μm but not 7 μm microsieves was positively 
correlated with fixation time (ρ=0.51, P<0.01). VyCAP detected CTC in 44% (12/27) of DLA products. 
Median CTC count per mL DLA was 0 [interquartile range (IQR): 0–1]. CellSearch detected CTC in 63% 
of DLA products (median =0.9 CTC per mL DLA, IQR: 0–2.1). CTC counts detected by CellSearch were 
significantly higher compared with VyCAP (P=0.05).
Conclusions: VyCAP microsieves can identify CTC in DLA product, but workflows need to be optimized. 
Keywords: Diagnostic leukapheresis (DLA); circulating tumor cell (CTC); non-small lung cancer (NSCLC); 
liquid biopsy; biomarker; VyCAP microsieves
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Introduction
Circulating tumor cell (CTC) have prognostic value in non-
small lung cancer (NSCLC) (1-5). However, in NSCLC 
CTC are detected in only 30% of metastatic NSCLC 
patients and in low frequencies of 1–2 CTC per 7.5 mL 
of blood (1-8). CTC are likely present in the majority of 
metastatic patients but the current available methods are 
only capable of screening limited volumes of blood (9,10). 
As CTC have a similar density as mononuclear cells they 
can be extracted from the blood by means of a diagnostic 
leukapheresis (DLA), allowing the screening of a large 
volume of blood for CTC (10-13). 
In the DLA product the CellSearch platform identifies 
CTC in higher frequencies and in more patients compared 
to peripheral blood (11-13). CellSearch uses positive 
immunomagnetic selection to extract the epithelial cell 
adhesion molecule (EpCAM) positive CTC. Due to the 
high numbers of leukocytes in the DLA product, which have 
non-specific interaction with the immunomagnetic particles 
targeting EpCAM, usage of the CellSearch platform in 
processing DLA is limited (11). VyCAP microsieves collect 
CTC by their relative size and rigidity, allowing for the 
detection of both EpCAM positive and negative cells (1-3). In 
addition, modified versions of these filters may allow isolation 
of single CTC for genomic analysis, or to perform functional 
tests in captured CTC (14-18). In this study we looked into the 
capability of VyCAP microsieves to filter the DLA product of 
NSCLC patients to enumerate CTC and compare the CTC 
counts per patient with those of CellSearch. 
Methods
Patient inclusion and clinical data
Consecutive patients with proven NSCLC starting their 
treatment were prospectively included in an exploratory 
cohort. Patients who had an Eastern Cooperative Oncology 
Group Performance Status (PS) of 0–2 and did not use 
anticoagulation medication or suffer from clotting disorders 
were selected. All patients gave informed consent. The 
study was approved by the regional Medical Ethical 
Committee (NL55754.042.15) and registered in the Dutch 
trial register (NL5423), conducted in accordance with the 
Declaration of Helsinki (as revised in 2013).
Diagnostic leukapheresis procedure
DLAs were performed with the Spectra Optia® Apheresis 
System using an intermediate density layer set (IDL) and 
software version 11 (Terumo BCT inc, Lakewood, CO, 
USA). The standard continuous MNC protocol was used 
with a packing factor of 4.5, collection pump set to 1 mL 
per minute, hematocrit minus 3 percent points and a 
flexible inlet flow. Anticoagulant Citrate Dextrose Solution 
A (ACDA) was used for anticoagulation in a dilution of 1:11, 
further adjusted when aggregate formation was observed in 
the collection chamber. 
We aimed to process the total blood volume (TBV) of the 
patient, as estimated with the formula of Nadler (19). DLA 
collection would be performed at a hematocrit around 5%. 
DLA procedure efficacy was measured by determining 
the percentage of lymphocytes that were captured 
compared to the number that passed through the machine 
(lymphocytes in DLA product divided by lymphocytes in 
blood that was processed). 
DLA product processing
A DLA aliquot with a volume equaling that of 2×108 
leukocytes was diluted with CellSearch Circulating Tumor 
Cell Kit Dilution Buffer (Menarini Silicon Biosystems, 
Huntingdon Valley, PA, USA) to 9 mL and transferred to a 
CTC-TVT Transfix tube (Cytomark, Buckingham, United 
Kingdom) and stored at room temperature for at least 24 h. 
The sample was filtered within 72 h after completion of the 
DLA procedure using two VyCAP microsieves. This filtration 
in two steps was because of the experiences in the CTC-
Trap study, where CTC were lost and only a small volume 
of DLA could be filtered (13). Filtration and CTC detection 
occurred according to manufacturer instructions [version 
2.1, September 2017 (20)]. Firstly, the whole DLA sample is 
filtered using a microsieve with pores of 7 μm using a pressure 
of 30–250 mbar. Subsequently, the 7 μm microsieve filtrate, 
collected in the waste compartment of the VyCAP disposable, 
was passed through a microsieve with 5 μm pores at a pressure 
of 150–250 mbar. Immediately after filtration, the cells on 
the filter are stained with immunofluorescent labels using 
a permeabilization buffer, followed by the addition of a 
staining cocktail containing pan-cytokeratin CK-11 (PE, Cell 
Signaling Technology, #5075S, clone C11), pan-cytokeratin 
AE1/AE3 (eFluor 570, eBioscience, 41-9003-82, clone AE1/
AE3), CD45 (APC, eBioscience, 17-0459-41/42, clone 
HI30) and CD16 (APC, BioLegend, #302011, clone 3G8). 
Mounting medium containing DAPI was added followed by 
the addition of a cover slip. The microsieves were scanned 
and images of the cells on the microsieves were acquired. 
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CTC, defined as cells expressing cytokeratins and containing 
a nucleus, but lacking CD45 and CD16 were counted. CTC 
counts are reported per mL DLA product. 
Two samples which clogged were additionally labeled 
with CD41 (FITC, BD Pharmingham, cat#557296) to 
detect platelets. In two patients a second DLA sample, in 
which ACDA was used to dilute the sample to 9 mL instead 
of CellSearch dilution buffer, was used to determine the 
influence of anticoagulants on the formation cell clusters 
and cell clumps in the DLA product. 
Comparison with CellSearch
We detected CTC in DLA product with CellSearch 
as previously described (13). In short, a DLA product 
volume containing in total 2×108 leukocytes was diluted 
to 7.5 mL with CellSearch dilution buffer in a CellSave 
CTC tube (Menarini siliconbiosystems, Bologna, Italy). 
CellSearch would then be used to identify CTC according 
to manufacturer’s instructions. 
Spiking tumor cells in DLA product
To determine the recovery of tumor cells in DLA product, 
DLA products of two patients were spiked with 384 and 
135 MCF-7 cells that were manually counted before 
transferring these to the DLA sample. MCF-7 cells were 
exposed to the sample concentration of transfix for the same 
times as the DLA samples. 
Results
NSCLC patients and apheresis
Twenty-nine NSCLC patients underwent an apheresis 
(Tables S1,S2). The median estimated patient total blood 
volume was 5.2 L [interquartile range (IQR): 4.7–5.8], of 
which 4.6 L (IQR: 3.9–5.5 L) was processed in 102 minutes 
(IQR: 87–110). DLA procedures had a median efficacy 
(%lymphocytes captured that passed through the machine) of 
57% (IQR: 55–65%). The median volume of DLA product 
was 88 mL (IQR: 70–96), including 12 mL ACDA (IQR: 
11–13) for anticoagulation. The total number of cells used 
for filtration was 2×108, which equaled a median volume of 
1.4 mL (IQR: 1.1–2.3) of DLA product, constituting 2.1% 
(IQR: 1.3–3.0%) of the total DLA product. CTC counts were 
determined using VyCAP filtration with 7 μm followed by 
5 μm microsieves (Figure 1).
Figure 1 Processing diagnostic leukapheresis (DLA) samples for circulating tumor cells (CTC) filtration.
2 aliqouts 
+ ACDA
7 μm pore microsieve
5 μm pore microsieve
Both failed
Additional citrate did not 
improve filtration
DLA in 29 patients
29 DLA products
- aliquots of 2×108 leukocytes-
aliquots diluted to 9 mL
- in Transfix tube
29 aliqouts 
+CellSearch dilution buffer









7 μm pore microsieve








7 μm pore microsieve  
CTC detected in 9/27 (33%)
5 μm pore microsieve
CTC detected in 5/13 (38%)
Total with CTC: 12/27 (44%)
13 × 7 μm + 5 μm microsieve
CTC: 7/13 (54%)
14 × only 7 μm microsieve
CTC: 5/14 (36%)
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DLA filtration through 7 μm sieves
Out of 29 DLA products (Table 1) that were filtered with the 
7 μm pore microsieves, 93% [27] succeeded. One sample 
failed to filtrate due to a technical issue and one due to 
clogging (processed at 72 hours after DLA). Failure of the 
sample to filtrate could not be associated with time between 
the DLA procedure and filtration (exposure time to 
fixative) or to cell counts in the DLA product (white blood 
cells, monocytes, lymphocytes, granulocytes, platelets, 
hematocrit). CTC were detected in 33% (9/27) successfully 
filtered samples. CTC counts ranged from 0–3 CTC per 
mL DLA product (median =0, IQR: 0–0.7).
DLA filtration through 5 μm filters
Only 45% (13/29) of filtrations through the 5 μm pore 
microsieves were successful, the others failed due to 
clogging of the filter. Neither cell counts in the DLA 
product nor DLA volume correlated to filtration failure. 
Only the time that DLA product was exposed to the fixative 
in the Transfix tube correlated positively with filtration 
failure (ρ=0.51, P<0.01). Out of 29 samples filtered with 
5 μm pore microsieves, 19 were processed 24 hours after 
DLA. Seven of these nineteen failed (36%). Seven samples 
were processed 48 hours after DLA, of which 6 failed (86%). 
Two samples were processed at 72 hours and both clogged. 
CTC were detected in 38% (5/13) of successfully filtered 
samples. CTC count ranged from 0–1.8 CTC per mL DLA 
product (median =0, IQR: 0–0.9). 
CD41 staining
On several filters cellular aggregates were observed (Figure 2A). 
To study the presence of platelets immunofluorescent staining 
with CD41 was performed. Accumulation was observed in the 
Table 1 Diagnostic leukapheresis aliquots (n=29) from non-small cell lung cancer patients, dilution material and volumes and cell counts and final 
concentrations processed and filtered to detect CTC
Variable In blood Vycap CellSearch
DLA aliquot
DLA product (mL) 0 1.4 (1.1–2.3) 1.4 (1.1–2.3)
Processed cells (absolute number of cells present in the sample)
Leukocytes (×106) 67.5 (57.0–87.8) 200* 200*
Lymphocytes (×106) 12 (8.3–15.8) 74.0 (50.8–107.9) 74.0 (50.8–107.9)
Monocytes (×106) 6.0 (5.3–8.3) 42.7 (30.0–49.1) 42.7 (30.0–49.1)
Granulocytes (×106) 49.5 (68.3–41.6) 99.2 (85.5–117.7) 99.2 (85.5–117.7)
Platelets (×106) 2,197 (1,646–2,891) 2,549 (1,964–4,282) 2,549 (1,964–4,282)
Erytrocytes (×109) 35.3 (31.4–36.9) 0.9 (0.5–1.3) 0.9 (0.5–1.3)
Dilution material and volume
Dilution material NA CellSearch buffer CellSearch buffer
Dilution volume (mL) 0 7.6 (6.7–7.9) 6.1 (5.2–6.4)
Total sample (mL) 7.5 9 7.5
Concentrations per mL filtrate
Leukocytes (×106/mL) 9.0 (7.6–11.7) 22.2 26.7
Lymphocytes (×106/mL) 1.6 (1.1–2.1) 8.2 (5.6–12.0) 9.9 (6.8–14.4)
Monocytes (×106/mL) 0.8 (0.7–1.1) 4.7 (3.3–5.5) 5.7 (4.0–6.6)
Granulocytes (×106/mL) 6.6 (5.6–9.1) 11.1 (9.5–13.1) 13.2 (11.4–15.7)
Platelets (×106/mL) 293.0 (219–385) 283 (218–476) 340 (262–571)
Erytrocytes (×109/mL) 4.7 (4.2–4.9) 0.1 (0.1–0.1) 0.1 (0.1–0.2)
*, standardized to a concentration of 200×106 leukocytes +maximal capacity of CellSearch.
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pores of the filters (Figure 2B), indicating aggregation of platelets. 
Additional anticoagulant
For two patients 2 DLA product samples of 2×108 
leukocytes were investigated. Each patient had one sample 
diluted with CellSearch dilution buffer and one sample 
with ACDA for additional anticoagulation. The samples 
were processed at 24 hours after the DLA procedure. Both 
samples, with and without extra ACDA, could only be 
filtered using the 7 μm pore microsieves. The 5 μm pore 
filters clogged. The number of detected CTC did not differ. 
The additional ACDA did not prevent the formation of 
clumps and clusters (Figure 2C).
Spiked CTC
For both spiked samples, only the filtration with the 7 μm 
microsieves was successful at 24 hours after DLA. Recovery 
percentage of MCF-7 cells was 73% and 99%. 
Figure 2 Clogged VyCAP microfilters: aggregates of cells (A), accumulation of CD41 (platelet marker) staining in pores of a sample 
processed without additional ACDA (B) and with additional ACDA (C).
Cells remaining on the microsieveswere fluorescently labeled. 
Cytokeratin (yellow), CD45/CD16 (red) and nuclei (DAPI, blue). 
Microsieve B and C were additionally stained for CD41 (platelet 
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CTC detection
In 27 out of 29 patients the DLA product was successfully 
filtered; in 2 patients filters could not be evaluated. Out 
of 27 filtered DLA products, 44% [12] contained CTC 
(Figure 3A,B). The 7 μm pore microsieves identified CTC 
in 33% (9/27) filtered DLA products. The 5 μm pore 
microsieve successfully processed 13 samples, of which 38% 
(n=5) contained CTC. In the whole population, 41% had 
CTC detected (12/27). The combined CTC count from 
both filters in all patients ranged from 0–3 CTC per mL 
DLA product (median=0, IQR: 0–1). Out of the 13 samples 
filtered by both filters, CTC were detected in 54% (7/13).
Comparison with CellSearch
CellSearch detected CTC in 63% (17/27) of the matched 
samples that successfully filtered with VyCAP (Table S3); 
Both samples that failed to filter had CTC detected by 
CellSearch. There was a low concordance between both 
methods. CellSearch detected CTC in 10 patients who were 
negative when processed by VyCAP, while VyCAP detected 
CTC in 5 patients that did not have CTC detected by 
CellSearch (Table S3). The proportion of patients with CTC 
detected did not differ significantly between CellSearch 
(63%) and VyCAP (44%, P=0.3). Combining the CellSearch 
and Vycap results, CTC were identified in 81% (22/27). 
Median CTC count detected by CellSearch was 0.9 per mL 
DLA product (IQR: 0–2.1). This was significantly higher 
than CTC counts detected by VyCAP (P=0.05). 
Discussion
The VyCAP microsieve filtration system is developed for 
Figure 3 Circulating tumor cells identified on VyCAP filters.
Cells remaining on the microsieveswere fluorescently labeled. 
Cytokeratin (yellow), CD45/CD16 (red) and nuclei (DAPI, blue). 
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7.5 mL blood samples to enumerate CTC. However, CTC 
are hardly detected in the peripheral blood of even advanced 
stage NSCLC patients. DLA has been shown to increase 
CTC yield (11-13). The current golden standard for CTC 
detection, the FDA cleared CellSearch system, is limited by 
the number of leukocytes it can process (11). In blood this 
poses no limitation, but in DLA product it severely restricts 
the volumes of DLA product that can be screened for 
CTC. Therefore, we attempted to use the VyCAP system 
to filter CTC from DLA product, which differentiates 
CTC based on their size and rigidity. We expected it to be 
less limited in the volume of DLA that could be processed. 
However, while the 7 μm microsieves filtered the majority 
of samples, the 5 μm VyCAP microsieves had problems 
with the formation of cell aggregates and the different 
composition of the DLA product, resulting in clogging of 
the microsieves. Fixation time was the only factor found to 
be associated with failure of samples to filter. The fixative 
is necessary to avoid the necessity to process the samples 
immediately after the DLA procedure. Although the 
underlying fixation process of the used fixative (Transfix) 
is unknown, it was demonstrated that the time the DLA 
samples was exposed to the fixative influences the ability 
of VyCAP microsieves to filtrate DLA product and detect 
CTC. Other parameters may also be of influence as 
well, e.g., the presence of debris in the Vycap disposable 
waste compartment, or temperature and leukapheresis 
composition. Though we found no association of filtration 
failure with platelet counts, we did observe platelets in the 
microsieves. Therefore, other anticoagulants may have 
beneficial effects on clogging. However, increasing the 
amount of ACDA for anticoagulation did not improve 
filtration. We believe that more research is required to 
optimize the protocol for processing DLA product with 
VyCAP microsieves before they can be effectively used.
While not yet optimized, we did observe a high recovery 
percentage of the spiked MCF-7 cells using only the 7 μm 
microsieve. Yet CTC were detected in less patients with 
the microsieves (44%) compared to CellSearch (63%). 
The number of detected CTC was also significantly lower 
by VyCAP, reinforcing results found by Andree et al. (13). 
When combining CTC counts from CellSearch and 
VyCAP, CTC detection increased to 81% of patients. 
In conclusion, the used VyCAP filtration is not suitable 
for DLA product due to clogging of the 5 μm microsieves. 
This appears to be caused by the time the DLA product 
is exposed to the fixative in the Transfix tubes. Workflows 
need to be optimized to be able to process DLA product 
and adjustments are necessary for filtration of larger DLA 
product volumes. 
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Smoking status, n [%]
Smokers 15 [52]
Previous 8 [21]








Squamous cell 6 [21]









Targeted therapy 6 [21]
Blood, median [IQR]
TBV (L) 5.2 [4.7–5.8]
Processed volume (L) 4.6 [3.9–5.5]
Percentage processed 97% [46–100%]
DLA product, median [IQR]
mL 88 [70–96]
ACDA 12 [11–13]
mL DLA processed 1.4 [1.1–2.3]
ECOG PS, Eastern Cooperative Oncology Group Performance 
Score; DLA, diagnostic leukapheresis procedure; SD, standard 
deviation; TBV, total blood volume; IQR, inter quartile range; 
ACDA, Anticoagulant Citrate Dextrose Solution A.
Table S2 Blood cell counts in DLA product per liter
Type blood cell Mean SD
Red blood cells (×1012/L) 0.6 0.28
Leukocytes (×109/L) 135 76
Lymfocytes (×109/L) 51.8 22
Monocytes (×109/L) 29 10
Granulocytes (×109/L) 62 30
Platelets (×109/L) 1540 377
Hemoglobin (mmol/L) 0.91 0.28
Hematocrit (%) 0.07 0.04
Table S3 Number of circulating tumor cells detected on Vycap microsieves and by CellSearch in non-small cell lung cancer patients (n=29)
Patient mL DLA CellSearch Vycap total Vycap 7μm pore Vycap 5μm pore
1 2.17 2 4 0 4
2 1.00 12 3 3 NA
3 2.99 0 3 2 1
4 1.16 0 3 1 2
5 1.03 1 2 2 NA
6 1.09 1 2 2 NA
7 1.40 3 1 1 0
8 1.24 0 1 1 NA
9 1.88 2 1 1 NA
10 0.75 0 1 0 1
11 1.53 11 1 1 0
12 2.41 0 1 0 1
13 0.98 0 0 0 0
14 1.37 0 0 0 0
15 1.86 1 0 0 0
16 2.52 3 0 0 0
17 0.54 2 0 0 0
18 0.56 2 0 0 0
19 1.09 0 0 0 NA
20 2.59 13 0 0 NA
21 1.67 0 0 0 NA
22 1.09 2 0 0 NA
23 1.31 1 0 0 NA
24 4.10 0 0 0 NA
25 2.16 6 0 0 NA
26 1.23 2 0 0 NA
27 2.37 4 0 0 NA
28 2.17 26 NA NA NA
29 2.74 1 NA NA NA
